XCUR
Exicure
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Bearish Engulfing
Price Hits New Low
Price Hits 52-week low
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About XCUR
Exicure, Inc.
An early-stage biotechnology company that developing nucleic acid therapies targeting RNA to address neurological disorders and hair loss disorders
2430 N. Halsted St., Chicago, IL 60614
--
Exicure, Inc., was founded on July 9, 2015. The company is a clinical-stage biotechnology company that develops treatments for immuno-oncology, inflammatory diseases and genetic diseases based on its proprietary spherical nucleic acid (SNA) technology.
Company Financials
EPS
XCUR has released its 2023 Q2 earnings. EPS was reported at -0.68, versus the expected 0.00, missing expectations. The chart below visualizes how XCUR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available